Indacaterol vs long‐acting beta2‐agonist alone
Mortality Deaths · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
- Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes onlyOR 1 [0.31, 3.28]4 studies · 3266 participantsModerate